| Japanese |
|---|
| Title | Prostatic Acid Phosphatase(PAP)のRadioimmunoassayによる前立腺癌のスクリーニングと治療効果の判定 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 三木誠*, 町田豊平*, 大石幸彦*, 木戸晃*, 柳沢宗利*, 吉田正林*, 東陽一郎*, 森川惇二** |
|---|
| Authors(kana) | |
|---|
| Organization | *東京慈恵会医科大学泌尿器科学教室, **栄研イムノケミカル研究所 |
|---|
| Journal | 核医学 |
|---|
| Volume | 18 |
|---|
| Number | 7 |
|---|
| Page | 941-946 |
|---|
| Year/Month | 1981/8 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 われわれが開発した前立腺性酸フォスファターゼ(PAP)測定用radioimmunoassay(RIA)を用いて, 656症例, 972検体の血清PAP値を測定した. 前立腺癌未治療例(28例)では, 血清PAP値3.0ng/ml以上の陽性率は82.1%であり, それらの最高値は4,260ng/mlであり, 治療例(94例)の陽性率は16.0%であった. 未治療例のstage別陽性率は, I, II, III, IVそれぞれ42.9%, 100%, 85.7%, 100%であり, 10ng/mlを越えた例はstageII以上の52.3%を占め100ng/mlを越えた例はstageIVの40%を占めた. 前立腺肥大症例(267例)では, 陽性率12.7%であったが最高値でも6.6ng/mlで, 10ng/mlを越える例はなかった. 他の疾患ではほとんど3.0ng/ml以下であった. また抗男性ホルモン療法に反応する例では, 早ければ1週, 遅くとも1月半以内に血清PAP値は正常域に下がった. 以上よりPAP,RIAによる前立腺癌のスクリーニングと, 治療効果の判定が可能であることを報告した. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Prostatic Acid Phosphatase(PAP), Radioimmunoassay, Prostatic Cancer |
|---|
| English |
|---|
| Title | The Value of PAP RIA in Screening Prostatic Cancer and in Detecting Therapeutic Effects |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Makoto MIKI*, Toyohei MACHIDA*, Yukihiko OHISHI*, Akira KIDO*, Munetoshi YANAGISAWA*, Masashige YOSHIDA*, Yoichiro HIGASHI*, Junji MORIKAWA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Urology, Jikei University School of Medicine, **Eiken Immunochemical Laboratory |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 18 |
|---|
| Number | 7 |
|---|
| Page | 941-946 |
|---|
| Year/Month | 1981/8 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] A double antibody radioimmunoassay(RIA)for human prostatic acid phosphatase(PAP)was developed. The normal upper limit of serum PAP level in the assay was set at 3.0 ng/ml. By the PAP RIA 972 serum samples from 656 patients, containing 122 patients with prostatic cancer(28 untreated and 94 treated), 267 with benign prostatic hyperplasia, 23 with prostatitis, 83 with other cancers and 126 with other benign diseaseg were studied. An elevated serum PAP was found in 82.1% of untreated patients with prostatic cancer, but in 16.0% of treated patients. Sera from untreated patients with prostatic cancer gave positive results in 3/7 of stage A, 4/4 of stage B, 6/7 of stage C and 10/10 of stage D. The highest value of them was 4260 ng/ml in a case of stage D, and all cases with serum PAP level exceeded 100 ng/ml were stage D prostatic cancers. While in 267 patients with benign prostatic hyperplasia, 34 cases(12.7%)had elevated serum PAP levels and the highest value of them was 6.6 ng/ml. Almost all serum PAP levels of patients with other diseases were normal. Based on these results, it is evident that the PAP RIA was efficient and distinguished for screening prostatic cancer and valuable for detecting the therapeutic effects. [Of screening prostatic cancer] serum PAP level 1)3.0-5.0 ng/ml - following up carefully. 2)over 5.0 ng/ml - prostatic cancer suspected. 3)over 10 ng/ml - prostatic cancer highly suspected. 4)over 100 ng/ml - prostatic cancer with metastasisly suspected. [Of detecting therapeutic effects of antiandrogentherapy] serum PAP level 1)decreasing in 10-14 days - effective. 2)non-decreasing in 10-14 days - non-effective. 3)increasing in controled patients - recurrent. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Prostatic Acid Phosphatase(PAP), Radioimmunoassay, Prostatic Cancer |
|---|